|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
||
|
a)
|
Name
|
Mr R G Connor
|
|
|
b)
|
Position/status
|
President, Global Manufacturing & Supply
|
|
|
c)
|
Initial
notification/
amendment
|
Initial notification
|
|
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||
|
a)
|
Name
|
GlaxoSmithKline plc
|
|
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||
|
a)
|
Description of
the financial instrument
|
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
|
|
|
b)
|
Nature of the
transaction
|
Following the vesting on 23 September 2016 of 50% of an award made
on 12 June 2014 under the GlaxoSmithKline Deferred Investment Award
Plan, Mr R Connor will receive a cash payment of £237,076.13
less applicable tax withholding in respect of 14,376.963 notional
Ordinary Shares.
|
|
|
c)
|
Price(s) and
volume(s)
|
Price(s)
|
Volume(s)
|
|
£16.49
|
14,376.963
notional Ordinary Shares.
|
||
|
d)
|
Aggregated
information
Aggregated
volume Price
|
n/a (single transaction)
|
|
|
e)
|
Date
of the transaction
|
2016-09-23
|
|
|
f)
|
Place
of the transaction
|
n/a
|
|
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
||
|
a)
|
Name
|
Mr S A Hussain
|
|
|
b)
|
Position/status
|
President, Global Pharmaceuticals
|
|
|
c)
|
Initial
notification/
amendment
|
Initial notification
|
|
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||
|
a)
|
Name
|
GlaxoSmithKline plc
|
|
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||
|
a)
|
Description of
the financial instrument
|
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
|
|
|
b)
|
Nature of the
transaction
|
Following the vesting on 23 September 2016 of 50% of an award made
on 12 June 2014 under the GlaxoSmithKline Deferred Investment Award
Plan, Mr Hussain will receive a cash payment of £296,345.16
less applicable tax withholding in respect of 17,971.204 notional
Ordinary Shares.
|
|
|
c)
|
Price(s) and
volume(s)
|
Price(s)
|
Volume(s)
|
|
£16.49
|
17,971.204
notional Ordinary Shares
|
||
|
d)
|
Aggregated
information
Aggregated
volume Price
|
n/a (single transaction)
|
|
|
e)
|
Date
of the transaction
|
2016-09-23
|
|
|
f)
|
Place
of the transaction
|
n/a
|
|
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
||
|
a)
|
Name
|
Mr D S Redfern
|
|
|
b)
|
Position/status
|
Chief Strategy Officer
|
|
|
c)
|
Initial
notification/
amendment
|
Initial notification
|
|
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||
|
a)
|
Name
|
GlaxoSmithKline plc
|
|
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||
|
a)
|
Description of
the financial instrument
|
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
|
|
|
b)
|
Nature of the
transaction
|
Following the vesting on 23 September 2016 of 50% of an award made
on 12 June 2014 under the GlaxoSmithKline Deferred Investment Award
Plan, Mr Redfern will receive a cash payment of £237,076.13
less applicable tax withholding in respect of 14,376.963 notional
Ordinary Shares.
|
|
|
c)
|
Price(s) and
volume(s)
|
Price(s)
|
Volume(s)
|
|
£16.49
|
14,376.963
notional Ordinary Shares
|
||
|
d)
|
Aggregated
information
Aggregated
volume Price
|
n/a (single transaction)
|
|
|
e)
|
Date
of the transaction
|
2016-09-23
|
|
|
f)
|
Place
of the transaction
|
n/a
|
|
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
||
|
a)
|
Name
|
Ms C Thomas
|
|
|
b)
|
Position/status
|
SVP, Human Resources
|
|
|
c)
|
Initial
notification/
amendment
|
Initial notification
|
|
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||
|
a)
|
Name
|
GlaxoSmithKline plc
|
|
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||
|
a)
|
Description of
the financial instrument
|
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
|
|
|
b)
|
Nature of the
transaction
|
Following the vesting on 23 September 2016 of 50% of an award made
on 12 June 2014 under the GlaxoSmithKline Deferred Investment Award
Plan, Ms Thomas will receive a cash payment of £237,076.13
less applicable tax withholding in respect of 14,376.963 notional
Ordinary Shares.
|
|
|
c)
|
Price(s) and
volume(s)
|
Price(s)
|
Volume(s)
|
|
£16.49
|
14,376.963
notional Ordinary Shares
|
||
|
d)
|
Aggregated
information
Aggregated
volume Price
|
n/a (single transaction)
|
|
|
e)
|
Date
of the transaction
|
2016-09-23
|
|
|
f)
|
Place
of the transaction
|
n/a
|
|
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
||
|
a)
|
Name
|
Dr P J T Vallance
|
|
|
b)
|
Position/status
|
President, Pharmaceuticals Research & Development
|
|
|
c)
|
Initial
notification/
amendment
|
Initial notification
|
|
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||
|
a)
|
Name
|
GlaxoSmithKline plc
|
|
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||
|
a)
|
Description of
the financial instrument
|
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
|
|
|
b)
|
Nature of the
transaction
|
Following the vesting on 23 September 2016 of 50% of an award made
on 12 June 2014 under the GlaxoSmithKline Deferred Investment Award
Plan, Mr Vallance will receive a cash payment of £296,345.16
less applicable tax withholding in respect of 17,971.204 notional
Ordinary Shares.
|
|
|
c)
|
Price(s) and
volume(s)
|
Price(s)
|
Volume(s)
|
|
£16.49
|
17,971.204
notional Ordinary Shares
|
||
|
d)
|
Aggregated
information
Aggregated
volume Price
|
n/a (single transaction)
|
|
|
e)
|
Date
of the transaction
|
2016-09-23
|
|
|
f)
|
Place
of the transaction
|
n/a
|
|